AML
News
Targeting STAT3 to prevent relapse in AML
Compounds that target a novel binding site on STAT3 may one day be used to prevent relapse in acute myeloid leukemia (AML), according to...
News
Groups crowd-source cancer research
Photo by Rhoda Baer In an attempt to crowd-source cancer research, a pair of Canadian organizations made a small molecule they developed freely...
News
Agent blocks STAT3 protein and might prevent AML relapse
News
Persistent mutations tied to relapse, death in AML
Mutations that persist after initial chemotherapy may confer an increased risk of relapse and poor survival in patients with acute myeloid...
News
Persistent mutations linked to poorer outcomes in AML
Key clinical point: Leukemia-associated mutations that persisted 30 days after chemotherapy initiation were associated with a significantly...
News
Outcomes worse with secondary and therapy-related AML compared with de novo AML
Key clinical point: Younger patients with secondary and therapy-related acute myeloid leukemia (sAML and tAML, respectively) have worse outcomes...
News
New HMA shows early promise for MDS/AML
Image by Christoph Bock Investigators say a novel hypomethylating agent (HMA) is safe and clinically active in patients with myelodysplastic...
News
Selinexor dose lowered due to sepsis in AML patients
Photo by Esther Dyson An excess of sepsis cases has prompted dose reductions in a phase 2 trial of selinexor in older patients with relapsed/...
News
Inhibitor could treat range of hematologic disorders
A small molecule that targets the sonic Hedgehog signaling pathway has advanced to phase 2 trials in a range of hematologic disorders. In a phase...
News
Analysis reveals potential therapeutic target for AML
The protein tetraspanin3 (Tspan3) plays a critical role in the development and progression of acute myeloid leukemia (AML), according to research...
News
Group creates mouse model of RUNX1-mutated AML
Researchers have developed a mouse model to help them understand why patients with RUNX1-mutated acute myeloid leukemia (AML) respond poorly to...